These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 15161930)

  • 41. Extensive in situ activation of nuclear estrogen receptors after exposure of murine uteri to [3H]estradiol or [3H]4-hydroxytamoxifen.
    Pavlik EJ; Nelson K; van Nagell JR; Donaldson ES; Walden ML; Gallion H; Kenady DE
    Endocrinology; 1987 Apr; 120(4):1608-14. PubMed ID: 3830064
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of Human SULT1E1 Polymorphisms on the Sulfation of 17β-Estradiol, 4-Hydroxytamoxifen, and Diethylstilbestrol by SULT1E1 Allozymes.
    El Daibani AA; Alherz FA; Abunnaja MS; Bairam AF; Rasool MI; Kurogi K; Liu MC
    Eur J Drug Metab Pharmacokinet; 2021 Jan; 46(1):105-118. PubMed ID: 33064293
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Structure-based discovery of pyrazolamides as novel ERRγ inverse agonists.
    Yang SH; Khadka DB; Han J; Na SY; Shin M; Kim DK; Oh BC; Kim EY; Choi HS; Cho WJ
    Eur J Med Chem; 2023 Mar; 250():115174. PubMed ID: 36805944
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Molecular basis of agonism and antagonism in the oestrogen receptor.
    Brzozowski AM; Pike AC; Dauter Z; Hubbard RE; Bonn T; Engström O; Ohman L; Greene GL; Gustafsson JA; Carlquist M
    Nature; 1997 Oct; 389(6652):753-8. PubMed ID: 9338790
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Estrogen receptor dimerization: ligand binding regulates dimer affinity and dimer dissociation rate.
    Tamrazi A; Carlson KE; Daniels JR; Hurth KM; Katzenellenbogen JA
    Mol Endocrinol; 2002 Dec; 16(12):2706-19. PubMed ID: 12456792
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Estrogen receptor-dependent and estrogen receptor-independent pathways for tamoxifen and 4-hydroxytamoxifen-induced programmed cell death.
    Obrero M; Yu DV; Shapiro DJ
    J Biol Chem; 2002 Nov; 277(47):45695-703. PubMed ID: 12244117
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mutations targeted to a predicted helix in the extreme carboxyl-terminal region of the human estrogen receptor-alpha alter its response to estradiol and 4-hydroxytamoxifen.
    Schwartz JA; Zhong L; Deighton-Collins S; Zhao C; Skafar DF
    J Biol Chem; 2002 Apr; 277(15):13202-9. PubMed ID: 11823467
    [TBL] [Abstract][Full Text] [Related]  

  • 48. 4-Hydroxytamoxifen is an isoform-specific inhibitor of orphan estrogen-receptor-related (ERR) nuclear receptors beta and gamma.
    Tremblay GB; Bergeron D; Giguere V
    Endocrinology; 2001 Oct; 142(10):4572-5. PubMed ID: 11564725
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells.
    Katzenellenbogen BS; Norman MJ; Eckert RL; Peltz SW; Mangel WF
    Cancer Res; 1984 Jan; 44(1):112-9. PubMed ID: 6537799
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of 4-hydroxytamoxifen, raloxifene and ICI 182 780 on survival of uterine cancer cell lines in the presence and absence of exogenous estrogens.
    Leblanc K; Sexton E; Parent S; Bélanger G; Déry MC; Boucher V; Asselin E
    Int J Oncol; 2007 Feb; 30(2):477-87. PubMed ID: 17203231
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists.
    Barkhem T; Carlsson B; Nilsson Y; Enmark E; Gustafsson J; Nilsson S
    Mol Pharmacol; 1998 Jul; 54(1):105-12. PubMed ID: 9658195
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The tamoxifen-responsive estrogen receptor alpha mutant D351Y shows reduced tamoxifen-dependent interaction with corepressor complexes.
    Yamamoto Y; Wada O; Suzawa M; Yogiashi Y; Yano T; Kato S; Yanagisawa J
    J Biol Chem; 2001 Nov; 276(46):42684-91. PubMed ID: 11553641
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Molecular sensors of estrogen receptor conformations and dynamics.
    Tamrazi A; Carlson KE; Katzenellenbogen JA
    Mol Endocrinol; 2003 Dec; 17(12):2593-602. PubMed ID: 12947047
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Differential interactions of estrogens and antiestrogens at the 17 beta-hydroxy or counterpart function with the estrogen receptor.
    Borgna JL; Scali J
    Eur J Biochem; 1991 Aug; 199(3):575-85. PubMed ID: 1868844
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Activation of a uterine insulin-like growth factor I signaling pathway by clinical and environmental estrogens: requirement of estrogen receptor-alpha.
    Klotz DM; Hewitt SC; Korach KS; Diaugustine RP
    Endocrinology; 2000 Sep; 141(9):3430-9. PubMed ID: 10965916
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Transcriptional regulation of the estrogen-inducible pS2 breast cancer marker gene by the ERR family of orphan nuclear receptors.
    Lu D; Kiriyama Y; Lee KY; Giguère V
    Cancer Res; 2001 Sep; 61(18):6755-61. PubMed ID: 11559547
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Identification of novel inverse agonists of estrogen-related receptors ERRγ and ERRβ.
    Yu DD; Huss JM; Li H; Forman BM
    Bioorg Med Chem; 2017 Mar; 25(5):1585-1599. PubMed ID: 28189393
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism.
    Shiau AK; Barstad D; Radek JT; Meyers MJ; Nettles KW; Katzenellenbogen BS; Katzenellenbogen JA; Agard DA; Greene GL
    Nat Struct Biol; 2002 May; 9(5):359-64. PubMed ID: 11953755
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A characteristic back support structure in the bisphenol A-binding pocket in the human nuclear receptor ERRγ.
    Liu X; Matsushima A; Shimohigashi M; Shimohigashi Y
    PLoS One; 2014; 9(6):e101252. PubMed ID: 24978476
    [TBL] [Abstract][Full Text] [Related]  

  • 60. FLP recombinase/estrogen receptor fusion proteins require the receptor D domain for responsiveness to antagonists, but not agonists.
    Nichols M; Rientjes JM; Logie C; Stewart AF
    Mol Endocrinol; 1997 Jun; 11(7):950-61. PubMed ID: 9178754
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.